A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
Publication
, Conference
Attia, S; Sankhala, KK; Riedel, RF; Robinson, SI; Conry, RM; Boland, PM; Barve, MA; Fritchie, K; Seon, BK; Alvarez, D; Adams, BJ; Shazer, RL ...
Published in: Journal of Clinical Oncology
May 20, 2016
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
11016 / 11016
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Attia, S., Sankhala, K. K., Riedel, R. F., Robinson, S. I., Conry, R. M., Boland, P. M., … Maki, R. G. (2016). A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). In Journal of Clinical Oncology (Vol. 34, pp. 11016–11016). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.11016
Attia, Steven, Kamalesh Kumar Sankhala, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Patrick McKay Boland, Minal A. Barve, et al. “A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).” In Journal of Clinical Oncology, 34:11016–11016. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.11016.
Attia S, Sankhala KK, Riedel RF, Robinson SI, Conry RM, Boland PM, et al. A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11016–11016.
Attia, Steven, et al. “A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 11016–11016. Crossref, doi:10.1200/jco.2016.34.15_suppl.11016.
Attia S, Sankhala KK, Riedel RF, Robinson SI, Conry RM, Boland PM, Barve MA, Fritchie K, Seon BK, Alvarez D, Adams BJ, Shazer RL, Theuer CP, Maki RG. A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 11016–11016.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
11016 / 11016
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences